Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Epidemiol Psychiatr Sci ; 31: e71, 2022 Oct 10.
Artigo em Inglês | MEDLINE | ID: mdl-36214322

RESUMO

AIMS: Recent estimates suggest that 40% of dementia cases could be avoided by treating recognised cardiovascular risk factors such as hypertension, diabetes, smoking and physical inactivity. Whether diet is associated with dementia remains largely unknown. We tested if low adherence to established dietary guidelines is associated with elevated lipids and lipoproteins and with increased risk of Alzheimer's disease and non-Alzheimer's dementia ­ a dementia subtype with a high frequency of cardiovascular risk factors. METHODS: We used the prospective Copenhagen General Population Study including 94 184 individuals with dietary information and free of dementia at baseline. Mean age at study entry was 58 years, and 55% (N = 51 720) were women and 45% (N = 42 464) were men. Adherence to dietary guidelines was grouped into low, intermediate and high adherence based on food frequency questionnaires. Main outcomes were non-Alzheimer's dementia and Alzheimer's disease. RESULTS: Low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol and plasma triglyceride levels were higher in individuals with intermediate and low adherence to dietary guidelines compared with individuals with high adherence (all p for trends <0.001). Age and sex-adjusted hazard ratios (HRs) for non-Alzheimer's dementia v. individuals with high adherence were 1.19 (95% confidence interval 0.97­1.46) for intermediate adherence, and 1.54 (1.18­2.00) for low adherence. Corresponding HRs in multivariable-adjusted models including APOE genotype were 1.14 (0.92­1.40) and 1.35 (1.03­1.79). These relationships were not observed in individuals on lipid-lowering therapy. CONCLUSIONS: Low adherence to national dietary guidelines is associated with an atherogenic lipid profile and with increased risk of non-Alzheimer's dementia ­ the subtype of dementia with a high frequency of vascular risk factors. This study suggests that implementation of dietary guidelines associated with an anti-atherogenic lipid profile could be important for prevention of non-Alzheimer's dementia.


Assuntos
Demência , Fidelidade a Diretrizes , Política Nutricional , Doença de Alzheimer/epidemiologia , Doença de Alzheimer/etiologia , Doença de Alzheimer/prevenção & controle , Apolipoproteínas E/genética , Demência/epidemiologia , Demência/etiologia , Demência/prevenção & controle , Feminino , Humanos , Lipídeos/análise , Lipoproteínas LDL/análise , Masculino , Pessoa de Meia-Idade , Estudos Prospectivos , Fatores de Risco , Triglicerídeos/análise
2.
Pharmazie ; 66(1): 11-6, 2011 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-21391429

RESUMO

In a previous study it has been demonstrated that a dissolution/permeation (D/P) system can discriminate between different immediate release fenofibrate formulations. The fractions permeated were correlated with fenofibrate's in vivo exposure in rats following p.o. administration. In the present study more detailed investigations are presented using data from six fenofibrate tablets tested in vivo in humans. In these pharmacokinetic studies no significant differences between formulations in AUC but in Cmax were found. Differences between the Cmax values were not explained by the dissolution characteristics of the tablets but were rationalized on the basis of micellar entrapment and diminished mobility of the active ingredient by surfactants in the formulations. This was demonstrated by a permeation system using dialysis membranes. Thus a permeation step in addition to dissolution measurement may significantly improve the establishment of an IVIV relationship.


Assuntos
Fenofibrato/administração & dosagem , Fenofibrato/farmacocinética , Hipolipemiantes/administração & dosagem , Hipolipemiantes/farmacocinética , Administração Oral , Adulto , Idoso , Algoritmos , Área Sob a Curva , Células CACO-2 , Química Farmacêutica , Cromatografia Líquida de Alta Pressão , Estudos Cross-Over , Diálise , Feminino , Humanos , Cinética , Masculino , Pessoa de Meia-Idade , Permeabilidade , Solubilidade , Espectrofotometria Ultravioleta , Comprimidos , Adulto Jovem
3.
Pharmazie ; 65(10): 723-8, 2010 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-21105572

RESUMO

In a previous study it has been demonstrated that a dissolution/permeation (D/P) system can discriminate between different immediate release fenofibrate formulations. The fractions permeated were correlated with fenofibrate's in vivo exposure in rats following p.o. administration. In the present study more detailed investigations are presented using data from six fenofibrate tablets tested in vivo in humans. In these pharmacokinetic studies no significant differences between formulations in AUC but in Cmax were found. Differences between the Cmax values were not explained by the dissolution characteristics of the tablets but were rationalized on the basis of micellar entrapment and diminished mobility of the active ingredient by surfactants in the formulations. This was demonstrated by a permeation system using dialysis membranes. Thus a permeation step in addition to dissolution measurement may significantly improve the establishment of an IVIV relationship.


Assuntos
Fenofibrato/farmacocinética , Hipolipemiantes/farmacocinética , Adulto , Idoso , Área Sob a Curva , Células CACO-2 , Química Farmacêutica , Cromatografia Líquida de Alta Pressão , Feminino , Fenofibrato/administração & dosagem , Fenofibrato/sangue , Meia-Vida , Humanos , Hipolipemiantes/administração & dosagem , Hipolipemiantes/sangue , Absorção Intestinal , Masculino , Pessoa de Meia-Idade , Solubilidade , Espectrofotometria Ultravioleta , Comprimidos , Equivalência Terapêutica , Adulto Jovem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...